There were two groups: group
A (n=73), with CABGs; and group B (n=1,223), without CABGs.
Results. Group A patients were more often male (86.3% versus 69.1%; P=.002), and more frequently had a history of diabetes, myocardial infarction and heart failure. Group B patients more frequently had ST-elevation myocardial infarction, and had a higher median ejection fraction (53% [interquartile range, 47%-60%] vs. 50% [42%-55%]; P<.01) and peak troponin-I concentration. There was no difference in see more the use of invasive techniques. Regarding medication, Group B patients were more likely to receive dual antiplatelet therapy at discharge. No significant difference was observed in in-hospital mortality (9.5% versus 5.9%; P=.2) or mortality at 1 month, 6 months or 1 year (9.8% versus 9.1%; log-rank test, P=.87) and the cumulative major adverse cardiac event rate was equally low in both groups. The presence
of a CABG was associated with more readmissions for unstable angina (11.3% vs. 3.1%; P<.01).
Conclusions. In our DUB inhibitor ACS patients, the presence of a CABG had no significant influence on short- or medium-term outcomes, such as all-cause mortality and adverse cardiac events.”
“Background: We undertook a meta-analysis to evaluate the accuracy of (18)FDG PET-CT for diagnosis of distant metastases in lung cancer patients.
Methods: Studies about (18)FDG PET-CT for diagnosis of distant metastases in patients with lung cancer were systematically searched in the MEDLINE and EMBASE databases. We calculated sensitivities, Histone Demethylase inhibitor specificities, positive likelihood ratios and negative likelihood ratios, and constructed summary receiver operating characteristic curves using bivariate regression models for (18)FDG PET-CT.
Results: Across 9 studies (780 patients), the sensitivity, specificity, positive likelihood
ratio and negative likelihood ratio of (18)FDG PET-CT were 0.93 (95% confidence interval [CI] = 0.88-0.96), 0.96 (95% CI = 0.95-0.96), 28.4 (95% CI = 14.0-57.5), and 0.08 (95% CI = 0.02-0.37), respectively. Overall weighted area under the curve was 0.98 (95% CI = 0.96-0.99).
Conclusion: (18)FDG PET-CT has excellent diagnostic performance for diagnosis of distant metastases in patients with lung cancer. (c) 2013 Elsevier Ltd. All rights reserved.”
“Parental effects arise when either the maternal or paternal phenotype influences the phenotypes of subsequent generations. Simple analytical models assume maternal effects are a mechanism creating delayed density dependence. Such models predict that maternal effects can very easily lead to population cycles. Despite this, unambiguous maternal-effect mediated cycles have not been demonstrated in any system. Additionally, much evidence has arisen to invalidate the underlying assumption that there is a simple positive correlation between maternal performance and offspring performance.